Corvus Pharmaceuticals, Inc. - Common Stock (CRVS)

Corvus Pharmaceuticals (NASDAQ:CRVS) reported a wider third-quarter loss as spending on clinical trials increased, while executives outlined a series of 2027 milestones for its lead experimental drug, soquelitinib. The company reported a net loss of $20.3 million for the third quarter of 2026, comp

Soquelitinib advances across multiple indications, with cash runway extended into 2028.

Corvus Pharmaceuticals (NASDAQ:CRVS) reported a wider second-quarter loss as it increased spending on clinical development of soquelitinib, its selective ITK inhibitor, while outlining expected milestones across programs in peripheral T-cell lymphoma, atopic dermatitis, hidradenitis suppurativa and

Immuno-oncology specialist Corvus Pharmaceuticals reported a recent insider buy amid a year of sharp share price gains.

This cloud-based payments provider delivers SaaS solutions to enterprise billers across utilities, finance, and healthcare sectors.

Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.

Corvus (CRVS) Q4 2025 Earnings Call Transcript

Corvus increased its public stock offering to $175 million from $150 million, making 7.9 million shares of its common stock available for purchase at Wednesday’s closing price of $22.15.

The update follows the company’s release of cohort 4 data from its atopic dermatitis study of Soquelitinib.

Early eczema trial success and heavy trading are rapidly reshaping how investors view this drug developer, today, Jan. 20, 2026.

Corvus Pharmaceuticals reported a narrower Q2 2025 loss of $0.10 per share, beating estimates, with shares rising 5.8% after-hours. Positive Phase 1 data for soquelitinib in atopic dermatitis boosted investor optimism.